R. Mueller

发表

Peripheral blood eosinophils and other non‐invasive biomarkers can monitor treatment response in eosinophilic oesophagitis

M. Vieth, A. Straumann, M. Bajbouj, 2015, Alimentary pharmacology & therapeutics.

504 A Double-Blind, Double-Dummy, Randomized, Controlled, Multicenter Trial On the Efficacy and Safety of Azathioprine Vs mesalamine for Prevention of Clinical Relapses in Crohn's Disease Patients with Postoperative Moderate or Severe Endoscopic Recurrence

W. Petritsch, M. Schwab, W. Reinisch, 2008 .

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

W. Petritsch, M. Schwab, W. Reinisch, 2010, Gut.

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn’s Disease

J. Langhorst, G. Rogler, F. Seibold, 2016, Journal of Crohn's & colitis.

Mucosal Improvement in Patients With Moderate to Severe Postoperative Endoscopic Recurrence of Crohn’s Disease and Azathioprine Metabolite Levels

W. Petritsch, M. Schwab, W. Reinisch, 2013, Inflammatory bowel diseases.

Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study.

M. Stolte, G. Baretton, S. Miehlke, 2009, Gastroenterology.

Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study

R. Mueller, R. Greinwald, O. Mickisch, 2013, Alimentary pharmacology & therapeutics.

Distribution of histopathological features along the colon in microscopic colitis

D. Aust, M. Vieth, S. Miehlke, 2020, International Journal of Colorectal Disease.

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis

M. Vieth, A. Straumann, M. Bajbouj, 2015, Gut.

Challenges and Opportunities in IBD Clinical Trial Design.

R. Collins, C. O'Morain, M. Silverberg, 2021, Gastroenterology.

Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?

J. Franklin, G. Terheggen, R. Mueller, 2013, Inflammatory bowel diseases.

Mesalazine granules are superior to Eudragit‐L‐coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis

L. Leifeld, P. Gibson, R. Pfützer, 2011, Alimentary pharmacology & therapeutics.

Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

A. Vcev, K. Dilger, R. Mueller, 2011, Alimentary pharmacology & therapeutics.

P608 Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: follow-up data of a randomised, double-blind, double-dummy, 1-year, multicentre trial

W. Petritsch, W. Reinisch, R. Mueller, 2013 .

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.

L. Kupčinskas, Z. Tulassay, G. Kiudelis, 2011, Journal of Crohn's & colitis.

Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.

M. Vieth, A. Bredenoord, A. Schoepfer, 2020, Gastroenterology.

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

L. Kupčinskas, K. Dilger, A. Dignass, 2014, Journal of Crohn's & colitis.

Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.

F. Lammert, M. Vieth, A. Bredenoord, 2019, Gastroenterology.

Ef ﬁ cacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial

M. Vieth, A. Bredenoord, A. Schoepfer, 2019 .

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

I. Gorelov, G. Kiudelis, R. Mueller, 2008, Gut.

Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitis

A. Lavy, L. Kupčinskas, R. Eliakim, 2007, Alimentary pharmacology & therapeutics.

T1124 Once Daily 3g Mesalamine Is the Optimal Dose for Maintaining Clinical Remission in Ulcerative Colitis: A Double-Blind, Double-Dummy, Randomized, Controlled, Dose-Ranging Study

R. Mueller, R. Greinwald, I. Rácz, 2008 .

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial

A. Öst, P. Hellström, J. Bohr, 2014, Gut.

CLINICAL—ALIMENTARY TRACT Budesonide Is Effective in Treating Lymphocytic Colitis: A Randomized Double-Blind Placebo-Controlled Study

M. Stolte, G. Baretton, S. Miehlke, 2009 .

Su1183 Topographical Distribution of Collagenous Colitis - A Pooled Histological Analysis of 2 European Prospective Multicenter Trials

D. Aust, M. Vieth, J. Bohr, 2013 .

Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)

D. Aust, J. Hampe, G. Baretton, 2014, BMC Gastroenterology.

Smoking Status Influences Clinical Outcome in Collagenous Colitis.

J. Bohr, C. Tysk, S. Miehlke, 2016, Journal of Crohn's & colitis.

Mo1129 – Efficacy of Budesonide Orodispersible Tablets for Induction of Remission in Patients with Active Eosinophilic Esophagitis: Results from the 6-Weeks Open-Label Treatment Phase of Eos-2 Trial

M. Vieth, A. Bredenoord, A. Straumann, 2019, Gastroenterology.

951a – Budesonide Orodispersible Tablets are Highly Effective to Maintain Clinico-Histological Remission in Adult Patients with Eosinophilic Esophagitis: Results from the 48-Weeks, Double-Blind, Placebo-Controlled, Pivotal Eos-2 Trial

M. Vieth, A. Bredenoord, A. Schoepfer, 2019, Gastroenterology.

Budesonide Orodispersible Tablets are Highly Effective for Treatment of Active Eosinophilic Esophagitis: Results from a Randomized, Double-Blind, Placebo-Controlled, Pivotal Multicenter Trial (EOS-1)

M. Vieth, A. Bredenoord, A. Schoepfer, 2017 .

83 Efficacy and Tolerability of a Once Daily Treatment with Budesonide Capsules Versus Mesalamine Granules for the Treatment of Active Ulcerative Colitis: A Randomized, Double-Blind, Double-Dummy, Multicenter Study

L. Kupčinskas, Z. Tulassay, G. Kiudelis, 2009 .

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme

M. Vieth, A. Bredenoord, A. Schoepfer, 2022, United European gastroenterology journal.

Fr170 BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY AFTER 6-WEEK TREATMENT IN ACTIVE EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A SUBSET ANALYSIS OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 TRIAL

A. Straumann, A. Lucendo, C. Schlag, 2021 .

W. Petritsch, M. Schwab, W. Reinisch, 2010, Gut.